Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With SOD1 -ALS.
Jennifer MorganrothTanya M BardakjianLaynie DratchColin C QuinnLauren B ElmanPublished in: Neurology. Clinical practice (2024)
As new therapies for neurologic diseases come to market, preparing for increased office volume and complex drug delivery are essential for optimal care.